Navigation Links
Actavis Launches Generic KADIAN® Capsules in the U.S.
Date:11/11/2011

MORRISTOWN, N.J., Nov. 11, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN®*.

Actavis has been manufacturing KADIAN® for 15 years and has in-depth expertise in the development and manufacturing of complex controlled-release pharmaceuticals.  

KADIAN® US sales have grown 50% in the last 5 years to approximately $275 million for the 12 months ending September 30, 2011, according to IMS Health.  

Please see full prescribing information at www.actavis.us/morphinesulfate

About Actavis:

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; and research and development facilities in Owings Mills, MD and Sunrise, FL. Please visit www.actavis.us for more information.

*KADIAN ® is a registered trademark of Actavis Elizabeth LLC.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Plans Latin America Expansion
2. Actavis Launches Generic Keppra XR® Tablets in the U.S.
3. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
4. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
5. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
6. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
7. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
8. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
9. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
10. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
11. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
Breaking Medicine News(10 mins):